7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Cancer Care

Active Surveillance for Prostate Cancer: When Watching Is the Plan and When It Changes

26 min read
Active Surveillance for Prostate Cancer: When Watching Is the Plan and When It Changes

Key Takeaways

  • In the ProtecT trial, prostate cancer deaths at 15 years were about 2.7 percent with monitoring, 2.2 percent with surgery and 2.9 percent with radiotherapy, differences that were not statistically significant.
  • Metastasis was roughly twice as common with monitoring in that trial (about 9.4 percent versus about 5 percent), which is why modern surveillance adds MRI and scheduled biopsies rather than relying on PSA alone.
  • Active surveillance includes repeat biopsies and aims to treat early if the cancer changes; watchful waiting skips biopsies and treats only symptoms, usually in men with limited life expectancy.
  • The confirmatory biopsy in the first year is the test most likely to change the plan, because it catches higher-grade cancer the first sampling missed.
  • A single raised PSA rarely triggers treatment; ejaculation, cycling, infection and benign enlargement all raise it, so teams act on trends and imaging.
  • After prostatectomy PSA should become undetectable within weeks, and only a confirmed rise on repeated tests, not a tiny fluctuation, signals possible recurrence.
Quick Answer

Active surveillance for prostate cancer means closely monitoring a low-risk, slow-growing tumor with regular PSA blood tests, MRI scans and periodic biopsies, and starting surgery or radiation only if the cancer shows signs of progressing. For carefully selected men, long-term trial data show prostate cancer deaths are similarly low whether they monitor or treat immediately, while surveillance delays or avoids treatment side effects. The decision always rests with the treating team.

The biopsy report arrives in a patient portal on a Tuesday afternoon, and one word in it rearranges the week: carcinoma. Then the urologist says something that sounds, at first, almost careless. We could just keep an eye on this. No operating room, no radiation schedule, just blood tests, a scan and another biopsy down the line.

That conversation, about active surveillance vs treatment for prostate cancer, is one of the strangest in modern medicine. You are being told you have cancer and, in the same breath, that the safest move might be to do nothing dramatic about it yet. Many men hear the second half as a dare.

The evidence behind that recommendation is unusually strong, and the reasoning is worth understanding in full, because “watching” is a plan with rules, triggers and an exit. This article walks through how it works, who it suits, what the long-term trials actually found, and the moments when watching stops being the plan.

How does active surveillance for prostate cancer actually work?

Active surveillance is a structured monitoring program, not an absence of care. The premise is simple: many prostate cancers grow so slowly that they may never cause harm during a man’s lifetime, so treatment can be deferred until there is evidence the tumor is changing. The word “active” matters. It signals scheduled tests with defined triggers, as opposed to waiting for symptoms.

Three tools do most of the work. The first is the PSA test, a blood test measuring prostate-specific antigen, a protein made by both normal and cancerous prostate cells. The second is multiparametric MRI, a detailed scan that can show whether a suspicious area is growing or new areas have appeared. The third is the prostate biopsy, in which small cores of tissue are sampled with a needle and graded under a microscope. According to Mayo Clinic, a typical surveillance program repeats PSA testing every few months, includes a digital rectal exam, and schedules repeat biopsies at intervals of one to three years, often guided by MRI.

Each result is compared with the last. A stable PSA, an unchanged MRI and a repeat biopsy that still shows low-grade cancer in a small volume mean the plan continues. A rise in grade, more cancer on biopsy or a clearly growing lesion on MRI means the conversation shifts toward treatment.

The goal is not to avoid treatment forever. It is to give treatment, with its real and sometimes permanent side effects, only to the men who need it, and only when they need it. Some men stay on surveillance for many years. Others move to treatment within the first year or two because a confirmatory biopsy found more than the first one did. Both outcomes are the program working as designed.

Active surveillance vs treatment for prostate cancer: what the trials show

The most informative evidence comes from the ProtecT trial in the United Kingdom, which randomly assigned more than 1,600 men with localized prostate cancer detected by PSA screening to active monitoring, surgery or radiotherapy, then followed them for a median of 15 years. The results, published in the New England Journal of Medicine and indexed on PubMed, reshaped how doctors talk about this decision.

Doctor consulting with older male patient in hospital room: Active surveillance vs treatment for prostate cancer: what the t

At 15 years, death from prostate cancer was uncommon in all three groups: about 2.7 percent with active monitoring, 2.2 percent with surgery and 2.9 percent with radiotherapy. Those differences were not statistically significant. Death from any cause was roughly 22 percent across the board, a reminder that for men in their 60s, heart disease and other illnesses are far more likely to be the story than a low-risk prostate tumor.

Two findings deserve equal weight, and honest reporting means giving them both. First, cancer spread to other parts of the body (metastasis) was more common in the monitoring group, about 9.4 percent, versus roughly 5 percent in each treatment group. Second, that higher rate of spread did not translate into more deaths from prostate cancer within 15 years. Interpreting those two facts together is the whole art of the decision.

One more detail from the same trial: most men in the monitoring group eventually received radical treatment at some point, while about a quarter were alive at 15 years without ever having been treated. Monitoring, for many, was a deferral rather than an avoidance.

Modern active surveillance is stricter than the ProtecT “active monitoring” arm, which relied mostly on PSA without routine MRI or scheduled biopsies. Current programs are designed to catch progression earlier, so the metastasis gap may be smaller today. That is an inference from guideline logic, not a proven number, and it is fair to say so.

What is non-aggressive prostate cancer?

Pathologists grade prostate cancer by how abnormal the cells look, using the Gleason system, which assigns a score based on the two most common patterns in the biopsy. That score is now translated into a simpler Grade Group from 1 to 5. Cleveland Clinic explains that Grade Group 1 (a Gleason score of 3+3=6) represents cells that still look fairly organized and tend to behave indolently, meaning they grow slowly and rarely spread.

“Non-aggressive” or “low-risk” prostate cancer generally means a combination of Grade Group 1, a PSA level in the lower range, and a tumor that cannot be felt on examination or appears small on MRI. Some men with Grade Group 2 disease (Gleason 3+4=7) with only a small amount of the higher-grade pattern are also considered candidates for surveillance under guidelines from organizations such as NICE and the NHS, a category sometimes called favorable intermediate risk.

Why does a slow-growing cancer still get the label? Because under the microscope it meets the definition. Some pathologists and researchers have argued that Grade Group 1 disease should be renamed to reduce fear-driven overtreatment, and that debate is ongoing. For now, the name stays, and the clinical reality is that most Grade Group 1 tumors would not threaten a man’s life if left alone for years.

The catch is sampling. A biopsy takes a dozen or so cores from an organ the size of a walnut. It can miss a higher-grade area. That is why the first year of surveillance usually includes a confirmatory biopsy, often MRI-targeted, to reduce the chance that “non-aggressive” was simply an incomplete picture. If that second look upgrades the cancer, it is not that the tumor changed; it is that the first sample missed something, and the plan is adjusted accordingly.

Who is usually offered active surveillance, and who is usually advised to treat now?

Guideline bodies, including the NHS and the organizations cited by Mayo Clinic, converge on a similar profile for surveillance: localized cancer confined to the prostate, Grade Group 1 or carefully selected Grade Group 2, a PSA that is not high for the size of the gland, and a man who is willing to attend regular tests and accept some uncertainty. Life expectancy matters too. A man likely to live another 15 or 20 years has more time for a slow cancer to become a problem, which is exactly why monitoring must be rigorous rather than relaxed for him.

Doctor consulting with mature male patient in clinical setting: Who is usually offered active surveillance, and who is usual

Men usually advised toward prompt treatment include those with Grade Group 3 or higher, those whose cancer has grown through the prostate capsule on MRI, those with rapidly rising PSA or high PSA density (PSA divided by prostate volume, which corrects for benign enlargement), and those whose biopsies show a large volume of cancer across many cores. Some inherited gene variants, such as BRCA2, also shift the discussion, because cancers in carriers can behave more aggressively.

There is a middle group where the choice is genuinely balanced, and here the man’s own values carry real weight. A 58-year-old with favorable intermediate-risk disease who dreads incontinence may reasonably choose surveillance. Another with the same report, who cannot tolerate living with an untreated cancer, may reasonably choose surgery. Neither is wrong, and neither should be pushed.

Age alone is not a disqualifier. Younger men can be surveilled, with the understanding that they are more likely to need treatment eventually. Older men with other serious illnesses may be steered toward a different plan entirely, discussed in the next section. In every case, the recommendation comes from the treating team after reviewing the full picture, not from a single number.

Watchful waiting vs active surveillance: why the two plans are not the same

The terms are often used interchangeably, and that confusion causes real misunderstanding. Both involve not treating the cancer right away. The intent behind them is completely different.

Active surveillance is for men who would be candidates for treatment with the aim of controlling the cancer long term. The plan deliberately keeps that option open. Monitoring is intensive, with repeat biopsies and scans, precisely because the team wants to catch progression while the cancer is still localized and treatable with surgery or radiation.

Watchful waiting, as the NHS describes it, is for men whose cancer is unlikely to affect their natural lifespan, usually because of advanced age or other serious health conditions, or for men who do not want radical treatment at all. There are no routine biopsies. The team checks in periodically and acts only if the cancer begins to cause symptoms, typically with hormone therapy, a class of medicines that lowers testosterone, the hormone that fuels prostate cancer growth. The aim is comfort and symptom control, not eliminating the tumor.

Put another way: surveillance asks “has anything changed?” at every visit and plans to intervene early. Watchful waiting asks “is this causing a problem?” and plans to intervene late, and gently. A man on watchful waiting who had a biopsy every two years would be undergoing an uncomfortable test with no purpose; a man on active surveillance who skipped biopsies would be taking a risk his plan was designed to avoid.

When a doctor says “we’ll keep an eye on it,” it is worth asking which of the two is meant. The answer changes what the next five years look like, and it changes what should prompt a phone call.

What the first months and years on surveillance usually look like

The rhythm of surveillance settles quickly, though the first year is busier than the ones that follow. Here is the typical shape, drawn from the monitoring schedules described by Mayo Clinic and the NHS; your own team’s protocol may differ.

In the first few months, expect a PSA test, often paired with a baseline MRI if one was not done before the diagnostic biopsy. Many programs then schedule a confirmatory biopsy within the first year, targeted to any MRI-visible lesion. This is the step most likely to change the plan, because it is the one most likely to reveal higher-grade cancer the first biopsy missed.

After that, PSA testing usually continues every three to six months, with a digital rectal exam about once a year. MRI is repeated at intervals or when PSA trends upward. Repeat biopsies are typically spaced one to three years apart, and some programs now lengthen that interval when MRI stays stable, reducing the number of needles over a lifetime.

Between tests, life is ordinary. There are no activity restrictions, no dietary rules specific to surveillance, and no reason to avoid travel. A biopsy itself usually means a day or two of discomfort, some blood in urine or semen for a few weeks, and a short course of antibiotics prescribed by the team to reduce infection risk.

The emotional timeline is less tidy. Many men describe the days before each PSA result as the hardest part of the whole arrangement, a phenomenon sometimes called scanxiety. It tends to ease as stable results accumulate. Building a predictable routine around the tests, and knowing in advance what result would trigger a change, helps more than any reassurance.

Active surveillance vs treatment prostate cancer: the trade-offs side by side

No option is free of cost to the body or the mind. The table below summarizes what each path typically involves, using findings from the ProtecT trial and the side-effect profiles described by the NHS and Mayo Clinic.

Consideration Active surveillance Surgery (prostatectomy) Radiation therapy
What happens Scheduled PSA, MRI, periodic biopsy; treat if progression Prostate removed, usually with robotic assistance External beam over weeks, or implanted seeds (brachytherapy)
Prostate cancer deaths at 15 years (ProtecT) About 2.7% About 2.2% About 2.9%
Metastasis at 15 years (ProtecT) About 9.4% About 4.7% About 5.0%
Main physical downsides Repeat biopsies (discomfort, infection risk); uncertainty Urinary leakage, erectile dysfunction, infertility Bowel irritation, urinary urgency, erectile changes that develop gradually
Main psychological downside Living with an untreated cancer Adjusting to permanent changes in function Longer treatment course; late side effects
Reversibility Can move to treatment at any point Not reversible Not reversible; surgery afterward is more difficult

Two things stand out. The mortality rows are nearly identical, which is the core argument for surveillance in low-risk disease. The metastasis row favors immediate treatment, which is the core argument against complacency, and the reason modern programs monitor more closely than the trial did.

The side-effect rows do not have percentages here because the figures vary widely by surgeon experience, technique, radiation dose and the man’s baseline function. Your team can describe their own outcomes. What is consistent across all mainstream sources is the direction: surgery carries the highest early risk to continence and erections, radiation carries more bowel-related effects, and surveillance defers both for as long as it continues.

What makes the plan change from watching to treating?

Surveillance has defined exits, and knowing them in advance removes much of the dread. The most common trigger is a change on biopsy: the cancer is upgraded from Grade Group 1 to Grade Group 2 or higher, or the number of involved cores or the percentage of each core rises beyond the threshold the program uses. Upgrading is the clearest signal that the tumor’s biology is different from what was first assumed.

MRI changes come next. A lesion that grows, becomes more suspicious, or appears to press against or through the capsule prompts a targeted biopsy, and often treatment if that biopsy confirms the finding.

PSA kinetics, meaning the pattern of change over time, are used more cautiously than they once were. A single high reading rarely triggers treatment on its own, because PSA rises with infection, recent ejaculation, vigorous cycling, a larger gland and even lab variation. A sustained upward trend, or a short PSA doubling time (the time it takes the value to double), prompts earlier imaging and biopsy rather than immediate treatment. The NHS and Mayo Clinic both describe PSA as a trigger for further tests, not a verdict.

Then there is the trigger no scan can measure: the man himself. Some men decide, after a year or two of stable results, that they no longer want to live with the uncertainty. Guidelines explicitly recognize patient preference as a legitimate reason to move to treatment, and a good team will not argue a man out of it.

What should not trigger a change is fear from a news headline or a friend’s experience. The question is always the same: has this specific cancer shown evidence of change, or has my tolerance for the plan changed? Either answer is valid. Only the first requires the tests to say so.

What does treatment involve if surveillance ends?

When the plan changes, the options are the same ones that were available at diagnosis, and the cancer is usually still localized because surveillance caught the change early. The two mainstays are surgery and radiation.

Radical prostatectomy removes the entire prostate gland and the seminal vesicles, most often through small incisions with robotic assistance. The urethra is reconnected to the bladder, which is why urinary leakage is common in the weeks and months afterward and improves for most men over time, according to the NHS. Nerves controlling erections run along the prostate and may be preserved or sacrificed depending on where the tumor sits. Recovery typically means a short hospital stay, a catheter for a period of days to weeks, and several weeks before normal activity.

Radiation therapy comes in two broad forms. External beam radiation delivers precisely shaped doses from outside the body over a course of sessions; shorter, higher-dose-per-session schedules are now common. Brachytherapy places radioactive seeds or temporary sources directly in the gland. Side effects tend to appear during or shortly after treatment (urinary urgency, bowel irritation, fatigue) and some, such as erectile changes, can emerge gradually over years. Intermediate-risk disease is sometimes paired with a limited course of hormone therapy, which lowers testosterone to make radiation more effective; the prescribing clinician decides whether that applies.

Focal therapies, which treat only the tumor-bearing part of the gland with heat, cold or focused ultrasound, exist and are attractive in concept. Mainstream guidelines still regard them as under evaluation for most men, with less long-term evidence than surgery or radiation, and they are generally offered within research settings or specialist programs rather than as a standard alternative.

Which option fits depends on tumor location, gland size, urinary function, other health conditions and personal priorities. That is a multidisciplinary conversation, and it belongs with the treating team.

Do prostate symptoms mean the cancer is growing?

Here is a point that reassures many men once it sinks in: localized, low-risk prostate cancer almost never causes symptoms. That is why it is found by PSA testing rather than by complaint. The common urinary symptoms men in their 50s, 60s and 70s experience, such as a weaker stream, getting up at night, hesitancy or a feeling of incomplete emptying, are overwhelmingly caused by benign prostatic hyperplasia (BPH), the non-cancerous enlargement of the gland that MedlinePlus describes as nearly universal with age.

The prostate wraps around the urethra like a ring around a straw. As the benign central tissue enlarges, it squeezes the tube. Most prostate cancers, by contrast, arise in the outer zone, away from the urethra, which is why they can grow for years without affecting urination at all. A man on surveillance who develops BPH symptoms is usually experiencing an unrelated process in the same organ.

That does not mean symptoms should be ignored. BPH is treatable, and it also raises PSA, which can muddy the surveillance picture; the team may use PSA density or a different trend baseline to account for it. Prostatitis, an inflammation or infection of the gland, can cause pain, fever and a sharp PSA spike that resolves after treatment.

Symptoms that would be more concerning for advanced cancer, such as persistent bone pain, unexplained weight loss or new difficulty passing urine that comes on quickly, are very unlikely in a man whose cancer was low risk and is being monitored, but they are the reason surveillance exists rather than neglect. The point is not to self-diagnose from a list. It is to report changes to the team, who can distinguish a benign explanation from something that needs a scan.

How does prostate cancer affect mental health while you watch and wait?

A cancer diagnosis without a treatment plan can feel like being handed a problem and told not to solve it. Men on surveillance describe a specific texture of worry: calm for months, then a tightening in the week before a PSA draw, then relief or dread depending on the number. Partners often carry a parallel anxiety that goes unspoken.

The research is more reassuring than intuition suggests. In the ProtecT trial, patient-reported anxiety and depression were similar across the monitoring, surgery and radiation groups over years of follow-up. Men who were treated did not, on average, buy peace of mind with their side effects, and men who were monitored did not, on average, pay for their intact function with chronic distress. Both groups adapted. That said, averages hide individuals, and a minority of men on surveillance do find the uncertainty intolerable; for them, choosing treatment is a legitimate mental-health decision.

Several things help. Understanding the actual numbers, rather than the word “cancer” alone, tends to shrink the fear to its real size. Knowing the specific triggers that would change the plan converts open-ended worry into a defined question. A consistent clinician who explains each result in context matters more than most men expect.

Depression and anxiety are treatable conditions, not character flaws, and they are common across every stage of prostate cancer, including the years after treatment when hormone therapy or changes in sexual function take a toll. Mayo Clinic and the NHS both recommend telling the care team about persistent low mood, loss of interest, sleep disruption or thoughts of self-harm. Psycho-oncology services, peer support groups and, where appropriate, counseling or medication prescribed by a clinician are part of cancer care, not a detour from it.

Is it normal for PSA levels to fluctuate, on surveillance and after prostatectomy?

Yes, and understanding why prevents a lot of unnecessary alarm. PSA is a living number. The protein is made by prostate tissue, and anything that irritates, enlarges or manipulates the gland pushes more of it into the bloodstream. Ejaculation within a day or two of the test, a long bike ride, a urinary infection, a recent rectal exam or biopsy, and ordinary lab-to-lab variation can all nudge the value. MedlinePlus and the NHS both note these effects. On surveillance, the team watches the trend over multiple readings rather than reacting to one, and a surprising value is usually repeated before anything else happens.

After radical prostatectomy the logic changes. With the gland gone, PSA should fall to an undetectable or near-undetectable level over the weeks following surgery, as the protein already in circulation clears. From then on, the test functions as a sensitive alarm: a measurable and rising PSA on repeated tests, a situation called biochemical recurrence, suggests that some prostate cells, benign or cancerous, remain somewhere in the body.

Small fluctuations at the very bottom of the detectable range are common with ultrasensitive assays and often mean nothing; a tiny rim of benign tissue left at the bladder junction can produce a stable low reading. What concerns clinicians is a confirmed upward trend over successive tests, and even then the next step is usually imaging and a discussion of options such as radiation to the prostate bed, with timing decided by the treating team.

After radiation, PSA behaves differently again: it falls gradually over a year or more, may show a temporary “bounce,” and never needs to reach zero because the gland remains. Each setting has its own definition of normal, which is why comparing numbers with another man’s, or with an online forum, rarely helps.

What people often get wrong about active surveillance

“They are just leaving the cancer in me.” They are, deliberately, because the evidence shows that for low-risk disease the cancer is far more likely to sit quietly than to spread, and because the monitoring is designed to catch it if it moves. Surveillance is a decision backed by 15-year trial data, not a shrug.

“Surveillance means no biopsies.” That describes watchful waiting. Active surveillance includes repeat biopsies, and the confirmatory one in the first year is the single most important test in the program.

“If I wait, I will lose the chance to be treated.” Most men who move from surveillance to treatment still have localized disease, and the ProtecT trial found no significant difference in prostate cancer deaths at 15 years between those who monitored and those who treated immediately. Delay is not the same as missing the window, provided the monitoring is actually done.

“A rising PSA means the cancer is growing.” It means further tests are needed. PSA rises for many benign reasons, and guidelines treat it as a prompt for imaging or biopsy rather than proof.

“Diet, supplements or a particular food will keep the cancer small.” No supplement has been shown in rigorous trials to prevent progression of prostate cancer, and the NIH Office of Dietary Supplements notes that some, such as high-dose vitamin E, have been linked to higher rather than lower risk in large studies. A heart-healthy pattern is sensible for the reasons that have nothing to do with the prostate. It is not a treatment.

“Surveillance is the cheap option.” It is a clinical recommendation grounded in avoiding harm. Treatment remains fully available to anyone whose cancer changes or who decides they want it.

“Men who choose surveillance are in denial.” The opposite is closer to the truth. Accepting a cancer diagnosis and still choosing the evidence-based path takes a clear head.

Questions to ask your care team

A good consultation leaves a man knowing exactly why surveillance was recommended for him, and exactly what would change the recommendation. These questions tend to draw out the answers that matter.

  • What is my Grade Group, my PSA density, and how many biopsy cores were involved? Which of those numbers made you suggest surveillance?
  • Was my MRI done before or after the biopsy, and was the biopsy targeted to anything the scan showed?
  • When is my confirmatory biopsy, and how likely is it, in your experience, to change the plan?
  • How often will I have PSA tests, scans and biopsies, and will the schedule relax if results stay stable?
  • What specific findings would move me from surveillance to treatment? Can you write them down?
  • If I do need treatment later, which option would you expect to recommend, and does waiting change that choice?
  • Do I have any family history or genetic factors that make surveillance riskier for me?
  • How should I handle a PSA result that comes back higher than expected? Who do I call?
  • Are there any activities, medicines or supplements that could interfere with my PSA readings?
  • Is there a nurse, counselor or support group attached to this program for the stretches between appointments?
  • If I decide at some point that I simply want treatment, will that be respected?

Bring someone to the appointment if you can. Partners and friends often remember the answers that fear pushes out of the patient’s head. It also helps to ask for a copy of the pathology report and the MRI summary, so that the numbers being discussed are the same ones in your own hands.

None of these questions should feel adversarial. Clinicians who recommend surveillance generally welcome them, because a man who understands the plan is far more likely to keep every appointment it depends on.

When to call your doctor

Low-risk prostate cancer on surveillance rarely causes emergencies, but the plan depends on prompt reporting of anything new, and a few situations deserve a same-day call or urgent care regardless of the cancer.

Seek urgent medical attention if you develop fever, chills or shaking within the days after a prostate biopsy. Infection after biopsy is uncommon but can progress quickly to sepsis, and the NHS advises treating these symptoms as an emergency. The same applies to being completely unable to pass urine (acute urinary retention), which is painful and needs catheterization.

Contact your team promptly, meaning within a day or two, if you notice blood in the urine that persists beyond the expected post-biopsy period or appears without a recent procedure, new and persistent pain in the lower back, hips or pelvis that does not settle with rest, unexplained weight loss, new weakness or numbness in the legs, or loss of bladder or bowel control. Leg weakness with back pain in anyone with a cancer diagnosis is treated as a possible spinal cord compression until proven otherwise, even though it is very unlikely in low-risk disease.

Call for a routine conversation, not an emergency, if a PSA result arrives that is higher than you expected, if you have missed or want to reschedule a surveillance test, if urinary symptoms are affecting your sleep or daily life, or if the waiting has become a persistent source of low mood or anxiety. These are exactly the issues the program exists to handle, and raising them early keeps the plan on track.

A short rule of thumb: sudden, severe or feverish means urgent; new, persistent or worrying means call; curious or uncertain means ask at the next visit, or sooner if it is keeping you up at night. Every decision about changing the plan rests with your treating team, who have the full picture of your results.

Frequently asked questions

What is non-aggressive prostate cancer, and does it really need to be called cancer?

Non-aggressive prostate cancer usually means Grade Group 1 (Gleason 3+3=6) disease with a low PSA and a small tumor confined to the gland. Under the microscope it meets the definition of cancer, which is why the name stays, but these tumors grow slowly and rarely spread. Some pathologists have proposed renaming Grade Group 1 to reduce overtreatment, and that debate continues. The practical point is that guidelines recommend monitoring rather than immediate treatment for most men in this category.

Watchful waiting vs active surveillance: which one am I actually on?

Ask your team directly, because the two plans have different goals. Active surveillance involves regular PSA tests, MRI and periodic biopsies, with the intention of treating early if the cancer progresses. Watchful waiting involves lighter check-ins without biopsies and treats symptoms if they arise, typically with hormone therapy, and is usually chosen for men with limited life expectancy or other serious illness. If you have been scheduled for a repeat biopsy, you are on active surveillance.

Is it normal for my PSA levels to fluctuate after prostatectomy?

Small fluctuations at the very bottom of the detectable range are common, especially with ultrasensitive tests, and often mean nothing. After the prostate is removed, PSA should fall to undetectable or near-undetectable levels within weeks. What clinicians watch for is a confirmed, rising value on successive tests, which is called biochemical recurrence and prompts imaging and a discussion of options. A single low reading is usually repeated before any conclusion is drawn.

How does prostate cancer affect mental health during surveillance?

Living with an untreated cancer can cause anxiety that peaks before each PSA result, and some men experience persistent low mood. Trial data from ProtecT found that anxiety and depression levels were similar whether men monitored or were treated immediately, suggesting most adapt over time. A minority find the uncertainty intolerable, and choosing treatment for that reason is legitimate. Tell your team about persistent low mood, poor sleep or loss of interest; support services are part of cancer care.

What are the common symptoms of prostate problems in men, and do they mean my cancer is growing?

Weak stream, nighttime urination, hesitancy and a feeling of incomplete emptying are common with age and are usually caused by benign prostate enlargement, not cancer. Low-risk prostate cancer typically causes no symptoms at all, because it arises away from the urethra. New symptoms should still be reported to your team, both because benign conditions are treatable and because they can raise PSA and confuse the surveillance picture. They rarely signal progression in monitored low-risk disease.

How long can a man safely stay on active surveillance?

There is no fixed limit. In the ProtecT trial, about a quarter of men in the monitoring group were alive at 15 years without ever having been treated, while most eventually received treatment at some point. Surveillance continues for as long as results stay stable and the man is comfortable with the plan. It ends when a biopsy, scan or PSA trend shows change, or when the man decides he prefers treatment. Both are normal outcomes.

Does active surveillance reduce my chance of being treated effectively later?

The available evidence says delay does not close the window, provided monitoring is actually done. In the ProtecT trial, prostate cancer deaths at 15 years did not differ significantly between men who monitored and men treated immediately, even though many monitored men were treated later. Metastasis was more common with monitoring, which is why current programs use MRI and scheduled biopsies to catch change earlier. Keeping every appointment is what protects the option of treatment.

What happens at the confirmatory biopsy, and why is it so important?

A confirmatory biopsy, usually within the first year and often targeted using MRI, re-samples the prostate to check that the first biopsy did not miss higher-grade cancer. Because a biopsy takes only a dozen or so cores from the gland, undersampling is the main reason a cancer labeled low risk later turns out to be more significant. If the second biopsy upgrades the cancer, treatment is usually recommended; if it confirms low-grade disease, surveillance continues with more confidence.

Can diet or supplements keep a low-risk prostate cancer from progressing?

No supplement has been shown in rigorous trials to prevent progression of prostate cancer, and the NIH Office of Dietary Supplements notes that high-dose vitamin E was associated with increased risk in a large trial. A heart-healthy eating pattern, regular physical activity and not smoking are sensible for overall health and for tolerating any future treatment. They should be seen as general health measures, not as a substitute for the monitoring schedule.

What are the main side effects I avoid by choosing surveillance?

Surveillance defers, for as long as it continues, the side effects of radical treatment. Surgery carries the highest early risk of urinary leakage and erectile dysfunction and always causes infertility. Radiation more often causes bowel irritation and urinary urgency, with erectile changes that can develop gradually over years. Surveillance has its own downsides, mainly the discomfort and small infection risk of repeat biopsies and the psychological weight of an untreated cancer. Your team can describe their own outcome figures.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 16, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.